CSIMarket Company Name, Ticker, Industry, else..
 
Emmaus Life Sciences Inc   (EMMAW)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 163
 Employees 35
 Revenues (TTM) (Millions $) 20
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Emmaus Life Sciences Inc
Emmaus Life Sciences Inc is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments for rare and orphan diseases. The company is best known for their flagship product, Endari, which is an oral powder indicated for the treatment of sickle cell disease. Endari is the first FDA-approved treatment for sickle cell disease in nearly 20 years. Emmaus Life Sciences Inc is committed to improving the lives of patients with rare diseases through their research, development, and commercialization efforts.


   Company Address: 21250 Hawthorne Boulevard Torrance 90503 CA
   Company Phone Number: 214-0065   Stock Exchange / Ticker: EMMAW


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMRN      % 
CORT      % 
CPRX      % 
SRPT      % 
TEVA      % 
VTRS      % 
• View Complete Report
   



Emmaus Life Sciences Inc

Emmaus Life Sciences Inc Reports Slight Revenue Growth in Q3 2023, Despite Mixed Financial Performance

In the July to September 30, 2023 financial period, Emmaus Life Sciences Inc experienced some positive and negative developments. The company reported a loss of $0.01 per share, which was the same as the previous year. However, this was an improvement from the loss of $0.03 per share in the prior reporting period.
Despite the loss, the company's revenue showed some growth. Revenue increased by 1.6% to $5.02 million from $4.94 million in the comparable reporting period a year before. However, there was a significant decrease in revenue compared to the previous quarter, with a decline of -53.36% from $10.76 million.
Emmaus Life Sciences Inc

Emmaus Life Sciences Inc Achieves Remarkable Performance in Recent fiscal period, Signaling Promising Future Prospects



Emmaus Life Sciences Inc, a prominent pharmaceutical company, has recently released its financial results for the most recent fiscal period, showcasing significant improvements across various key performance indicators. These impressive results have sparked curiosity about how they will shape the company's future prospects. This article delves into the implications of these findings and speculates on the possible impacts they may have on Emmaus Life Sciences Inc moving forward.
1. Decrease in Loss and Improved Income:
In the latest fiscal period, Emmaus Life Sciences Inc witnessed a notable reduction in loss per share, plummeting from $-0.18 to $-0.03 compared to the same period the previous year. Moreover, the company displayed considerable progress in its income per share, with a growth from $-0.07 in the previous reporting period. These statistics suggest that Emmaus Life Sciences Inc's efforts to cut costs and enhance revenue generation have been successful.
Emmaus Life Sciences Inc

Emmaus Life Sciences Inc. Showcases Remarkable Revenue Surge in Q1 2023, Yet Remains Steadfast in Pursuit of Profitability

Emmaus Life Sciences Inc. has recently announced excellent financial results with a staggering year-on-year revenue growth of 108.813% amounting to $6.75 million in the first quarter of 2023. However, it is worth noting that Emmaus recorded an increased shortfall per share of $-0.07, a significant jump from $0.00 per share reported in the prior period. Despite this, the company's revenue has surged upwards by 13.879% compared to the previous year's $5.93 million.
The fiscal time-frame ending March 31, 2023, saw Emmaus Life Sciences Inc. record a net shortfall of $-3.527 million, which is considerably higher than the $-1.542 million realized in the previous year.






Emmaus Life Sciences Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com